次世代がん診断の世界市場の規模と予測:技術別(NGS、LOACおよびRT-PCR)、用途別(CTC、バイオマーカー)、がん別(肺、乳房)、機能コンパニオン診断別、動向分析、2013-2024

◆英語タイトル:Next Generation Cancer Diagnostics Market Size & Forecasts By Technology (NGS, LOAC & RT-PCR), By Application (CTC, Biomarker), By Cancer Type (Lung, Breast), By Function Companion Diagnostics), And Trend Analysis, 2013 - 2024
◆商品コード:GVIEW707584
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2017年1月4日
◆ページ数:138
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:Biotechnology
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi UserUSD7,950 ⇒換算¥874,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD9,950 ⇒換算¥1,094,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、次世代がん診断の世界市場について調査・分析し、次世代がん診断の世界市場動向、次世代がん診断の世界市場規模、市場予測、セグメント別次世代がん診断市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global next generation cancer diagnostics market is anticipated to reach USD 11.04 billion by 2024, according to a new report by Grand View Research, Inc. Key drivers for this vertical include rising advancement in genomics and proteomics-based research coupled with increasing prevalence of oncology disorders.
Rise in number of oncological research projects to elucidate tumorigenesis and the underlying mechanisms, consequently raising the demand for serial sampling, diagnosis, and therapeutic manipulation, is a growth rendering driver of this market.

Further Key Findings from the Study Suggest:

The qPCR & multiplexing segment captured the largest market share in 2015 owing to the presence of a wide product portfolio serving numerous applications in oncology R&D

Next generation sequencing services and solutions for oncology applications are anticipated to be the fastest growing segment

Oncology diagnostics in biomarker discovery is expected witness growth as it subsequently facilitates drug designing and identification of novel targets against tumors

On the basis of cancer type, this vertical is segmented into lung, breast, colorectal, cervical, and other forms of cancer

Research projects to establish the therapeutic index of anticancer cytotoxic drugs are one of the key factors responsible for expected growth

North America dominated the market with respect to revenue generation in 2014 due to concerted efforts directed toward the development of next generation sequencing technology and companion diagnostics in personalized medicine

Some of the key players contributing significantly to the next generation cancer diagnostics market are Novartis AG; Cepheid; Hoffman La Roche Ltd.; PerkinElmer, Inc.; Sysmex Corporation; Abbott; Thermo Fisher Scientific, Inc.; Koninklijke Philips N.V.; Agilent Technologies; Illumina, Inc.; Genomic Health, Inc.; Qiagen; Janssen Global Services, LLC; Hologic, Inc.; Myriad Genetics, Inc.; Almac Group; Opko Health, Inc.; and GE Healthcare.

【レポートの目次】

Table of Contents

Chapter 1 Executive Summary
Chapter 2 Next Generation Cancer Diagnostics Industry Outlook
2.1 Market segmentation
2.2 Market size and growth prospects, 2013 – 2024
2.3 Next generation cancer diagnostics market dynamics
2.3.1 Market driver analysis
2.3.1.1 Exponentially decreasing cost of genetic sequencing
2.3.1.2 Development of cluster chip technology and potential applications of CTC in cancer management
2.3.1.3 Rising demand for preventive medicine & companion diagnostics
2.3.1.4 Growing cancer incidence
2.3.2 Market restraint analysis
2.3.2.1 Requirement of expensive laboratory set-up for implementation of novel tests
2.4 Key Opportunities Prioritized
2.5 Industry analysis – Porter’s
2.6 Next Generation Cancer Diagnostics PESTEL Analysis
Chapter 3 Next Generation Cancer Diagnostics Technology Outlook
3.1 Global next generation cancer diagnostics revenue share, by technology, 2015 & 2024
3.2 NGS-based cancer diagnostics
3.2.1 NGS-based cancer diagnostics market, 2013 – 2024 (USD Million)
3.3 qPCR & Multiplexing
3.3.1 qPCR & multiplexing-based market, 2013 – 2024 (USD Million)
3.4 Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
3.4.1 LOAC & RT-PCR-based market, 2013 – 2024 (USD Million)
3.5 Protein microarrays-based cancer diagnostics
3.5.1 Protein microarraysmarket, 2013 – 2024 (USD Million)
3.6 DNA microarrays-based cancer diagnostics
3.6.1 DNAmicroarrays-based cancer diagnosticsmarket, 2013 – 2024 (USD Million)
Chapter 4 Next Generation Cancer Diagnostics Outlook by Cancer Type
4.1 Global next generation cancer diagnostics revenue share, by cancer type, 2015&2024
4.2 Lung cancer
4.2.1 NGCD for lung cancer market, 2013 – 2024 (USD Million)
4.3 Breast cancer
4.3.1 NGCD for breast cancer market, 2013 – 2024 (USD Million)
4.4 Colorectal cancer
4.4.1 NGCD for colorectal cancer market, 2013 – 2024 (USD Million)
4.5 Cervical cancer
4.5.1 NGCD for cervical cancer market, 2013 – 2024 (USD Million)
4.6 Other types of cancer
4.6.1 NGCD for other forms of cancer market, 2013 – 2024 (USD Million)
Chapter 5 Next Generation Cancer Diagnostics Outlook by Application Outlook
5.1 Global next generation cancer diagnostics revenue share, by application, 2015&2024
5.2 Biomarker development
5.2.1 NGCD for biomarker development market, 2013 – 2024 (USD Million)
5.3 CTC analysis
5.3.1 NGCD for CTC analysis market, 2013 – 2024 (USD Million)
5.4 Proteomic analysis
5.4.1 NGCD for proteomic analysis market, 2013 – 2024 (USD Million)
5.5 Epigenetic analysis
5.5.1 NGCD for epigenetic analysis market, 2013 – 2024 (USD Million)
5.6 Genetic analysis
5.6.1 NGCD for genetic analysismarket, 2013 – 2024 (USD Million)
Chapter 6 Next Generation Cancer Diagnostics Outlook by Function
6.1 Global next generation cancer diagnostics revenue share, by function, 2015&2024
6.2 Therapeutic monitoring
6.2.1 NGCD for therapeutic monitoring market, 2013 – 2024 (USD Million)
6.3 Companion diagnostics
6.3.1 NGCD for companion diagnostics market, 2013 – 2024 (USD Million)
6.4 Prognostic diagnostics
6.4.1 NGCD for prognostics market, 2013 – 2024 (USD Million)
6.5 Cancer screening
6.5.1 NGCD for cancer screening market, 2013 – 2024 (USD Million)
6.6 Risk analysis
6.6.1 NGCD for risk analysis market, 2013 – 2024 (USD Million)
Chapter 7 Next Generation Cancer Diagnostics Regional Outlook
7.1 Global next generation cancer diagnostics revenue share, by region, 2015 & 2024
7.2 North America
7.2.1 North America next generation cancer diagnostics market, 2013 – 2024 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. next generation cancer diagnostics market, 2013 – 2024 (USD Million)
7.2.3 Canada
7.2.3.1 Canada next generation cancer diagnostics market, 2013 – 2024 (USD Million)
7.3 Europe
7.3.1 Europe next generation cancer diagnostics market, 2013 – 2024 (USD Million)
7.3.2 Germany
7.3.2.1 Germany next generation cancer diagnostics market, 2013 – 2024 (USD Million)
7.3.3 France
7.3.3.1 France next generation cancer diagnostics market, 2013 – 2024 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific next generation cancer diagnostics market, 2013 – 2024 (USD Million)
7.4.2 Japan
7.4.2.1 Japan next generation cancer diagnosticsmarket, 2013 – 2024 (USD Million)
7.4.3 China
7.4.3.1 China next generation cancer diagnostics market, 2013 – 2024 (USD Million)
7.5 Latin America
7.5.1 Latin Americanext generation cancer diagnosticsmarket, 2013 – 2024 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil next generation cancer diagnostics market, 2013 – 2024 (USD Million)
7.6 MEA
7.6.1 MEA next generation cancer diagnostics market, 2013 – 2024 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa next generation cancer diagnostics market, 2013 – 2024 (USD Million)
Chapter 8 Competitive Landscape
8.1 Janssen Global Services, LLC
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 F. Hoffmann-La Roche Ltd
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Koninklijke Philips N.V.
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Abbott
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.6 GE Healthcare
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Thermo Fisher Scientific, Inc.
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 Agilent Technologies (Dako)
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 Illumina, Inc.
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 Qiagen
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.10.4 Strategic Initiatives
8.11 Cepheid
8.11.1 Company Overview
8.11.2 Financial Performance
8.11.3 Product Benchmarking
8.11.4 Strategic Initiatives
8.12 Opko Health, Inc.
8.12.1 Company Overview
8.12.2 Financial Performance
8.12.3 Service Benchmarking
8.12.4 Strategic Initiatives
8.13 Hologic, Inc (Gen-Probe)
8.13.1 Company Overview
8.13.2 Financial Performance
8.13.3 Product Benchmarking
8.13.4 Strategic Initiatives
8.14 Perkin Elmer, Inc.
8.14.1 Company Overview
8.14.2 Financial Performance
8.14.3 Product Benchmarking
8.14.4 Strategic Initiatives
8.15 Sysmex Corporation
8.15.1 Company Overview
8.15.2 Financial Performance
8.15.3 Product Benchmarking
8.15.4 Strategic Initiatives
8.16 Myriad Genetics, Inc.
8.16.1 Company Overview
8.16.2 Financial Performance
8.16.3 Product Benchmarking
8.16.4 Strategic Initiatives
8.17 Almac Group
8.17.1 Company Overview
8.17.2 Financial Performance
8.17.3 Product Benchmarking
8.17.4 Strategic Initiatives
8.18 Exosome Diagnostics, Inc.
8.18.1 Company Overview
8.18.2 Financial Performance
8.18.3 Product Benchmarking
8.18.4 Strategic Initiatives
8.19 Genomic Health, Inc.
8.19.1 Company Overview
8.19.2 Financial Performance
8.19.3 Product Benchmarking
8.19.4 Strategic Initiatives

List of Figures

FIG. 1 Next generation cancer diagnostics market segmentation
FIG. 2 Global next generation cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 3 Next generation cancer diagnostics market dynamics
FIG. 4 Cost per raw mega base (Mb) of DNA sequence
FIG. 5 Cost per genome sequencing
FIG. 6 Key opportunities prioritized, 2015 & 2024
FIG. 7 Next generation cancer diagnostics market Porter’s analysis
FIG. 8 Next generation cancer diagnostics market PESTEL analysis
FIG. 9 Global next generation cancer diagnostics revenue share, by technology, 2015 & 2024
FIG. 10 NGS-based cancer diagnostics market , 2013 - 2024 (USD Million)
FIG. 11 qPCR & Multiplexing based market, 2013 - 2024 (USD Million)
FIG. 12 LOAC & RT-PCR-based market , 2013 - 2024 (USD Million)
FIG. 13 Protein microarrays market, 2013 - 2024 (USD Million)
FIG. 14 DNA microarrays-based cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 15 Global next generation cancer diagnostics revenue share, by application, 2015 & 2024
FIG. 16 NGCD for lung cancer market , 2013 - 2024 (USD Million)
FIG. 17 NGCD for breast cancer market , 2013 - 2024 (USD Million)
FIG. 18 NGCD for colorectal cancer market , 2013 - 2024 (USD Million)
FIG. 19 NGCD for cervical market, 2013 - 2024 (USD Million)
FIG. 20 NGCD for other forms of cancer market, 2013 - 2024 (USD Million)
FIG. 21 Global next generation cancer diagnostics revenue share, by application, 2015 & 2024
FIG. 22 NGCD for biomarker development market , 2013 - 2024 (USD Million)
FIG. 23 NGCD for CTC analysis market , 2013 - 2024 (USD Million)
FIG. 24 NGCD for proteomic analysis market , 2013 - 2024 (USD Million)
FIG. 25 NGCD for epigenetic analysis market, 2013 - 2024 (USD Million)
FIG. 26 NGCD for genetic analysis market, 2013 - 2024 (USD Million)
FIG. 27 Global next generation cancer diagnostics revenue share, by function, 2015 & 2024
FIG. 28 NGCD for therapeutic monitoring market , 2013 - 2024 (USD Million)
FIG. 29 NGCD for companion diagnostics market , 2013 - 2024 (USD Million)
FIG. 30 NGCD for prognostics market , 2013 - 2024 (USD Million)
FIG. 31 NGCD for cancer screening market, 2013 - 2024 (USD Million)
FIG. 32 NGCD for risk analysis market, 2013 - 2024 (USD Million)
FIG. 33 Global next generation cancer diagnostics revenue share, by region, 2015 & 2024
FIG. 34 North America next generation cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 35 Estimated number of new cancer cases and deaths in the U.S., 2015
FIG. 36 U.S. next generation cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 37 Canada next generation cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 38 Europe next generation cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 39 Germany next generation cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 40 France next generation cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 41 Asia Pacific next generation cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 42 Japan next generation cancer diagnosticsmarket, 2013 - 2024 (USD Million)
FIG. 43 China next generation cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 44 Latin America next generation cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 45 Brazil next generation cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 46 MEA next generation cancer diagnostics market, 2013 - 2024 (USD Million)
FIG. 47 South Africa next generation cancer diagnostics market, 2013 - 2024 (USD Million)

List of Tables

TABLE 1 Next Generation Cancer Diagnostics - Industry Snapshot &Key Buying Criteria, 2013 - 2024
TABLE 2 Global next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 3 Global next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 4 Global next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 5 Global next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 6 Global next generation cancer diagnostics market, by region 2013 - 2024 (USD Million)
TABLE 7 Next generation cancer diagnostics key market driver analysis
TABLE 8 Global cancer incidence, 2012
TABLE 9 North America cancer incidence in 2012
TABLE 10 Europe cancer incidence, 2012
TABLE 11 Asia cancer incidence, 2012
TABLE 12 Africa cancer incidence, 2012
TABLE 13 Australia and New Zealand cancer incidence in 2012
TABLE 14 Next generation cancer diagnostics key market restraint analysis
TABLE 15 North America next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 16 North America next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 17 North America next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 18 North America next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 19 U.S. next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 20 U.S. next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 21 U.S. next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 22 U.S. next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 23 Canada next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 24 Canada next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 25 Canada next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 26 Canada next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 27 Europe next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 28 Europe next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 29 Europe next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 30 Europe next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 31 Germany next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 32 Germany next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 33 Germany next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 34 Germany next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 35 France next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 36 France next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 37 France next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 38 France next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 39 Asia Pacific next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 40 Asia Pacific next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 41 Asia Pacific next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 42 Asia Pacific next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 43 Japan next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 44 Japan next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 45 Japan next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 46 Japan next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 47 China next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 48 China next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 49 China next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 50 China next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 51 Latin America next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 52 Latin America next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 53 Latin America next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 54 Latin America next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 55 Brazil next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 56 Brazil next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 57 Brazil next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 58 Brazil next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 59 MEA next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 60 MEA next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 61 MEA next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 62 MEA next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)
TABLE 63 South Africa next generation cancer diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 64 South Africa next generation cancer diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 65 South Africa next generation cancer diagnostics market, by cancer type, 2013 - 2024 (USD Million)
TABLE 66 South Africa next generation cancer diagnostics market, by function, 2013 - 2024 (USD Million)



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 次世代がん診断の世界市場の規模と予測:技術別(NGS、LOACおよびRT-PCR)、用途別(CTC、バイオマーカー)、がん別(肺、乳房)、機能コンパニオン診断別、動向分析、2013-2024(Next Generation Cancer Diagnostics Market Size & Forecasts By Technology (NGS, LOAC & RT-PCR), By Application (CTC, Biomarker), By Cancer Type (Lung, Breast), By Function Companion Diagnostics), And Trend Analysis, 2013 - 2024 )]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆